Artikelaktionen

Sie sind hier: FRIAS Fellows Fellows 2021/22 Prof. Dr. Manfred Jung

Prof. Dr. Manfred Jung

Albert-Ludwigs-Universität Freiburg
Pharmazeutische & Medizinische Chemie
Internal Senior Fellow
Oktober 2016 - Juli 2017

CV

Manfred Jung obtained his PhD on the synthesis of aromatic retinoids at the University of Marburg in 1993. From 1993 to 1994 he did a postdoc with T. Durst at the University of Ottawa (Canada). From 1994 to 2003 he was a group leader at the University of Münster and obtained his habilitation in Pharmaceutical Chemistry in 2000. Since 2003 he is a Professor of Pharmaceutical Chemistry at the University of Freiburg. In 2010 he received an offer for a full professorship to the University of Mainz that he declined and he is a Full Professor in Freiburg since 2011. He is currently the Dean of the Faculty of Chemistry and Pharmacy. The topic of his research is Chemical Epigenetics with a major focus on histone modifying enzymes. His group is working on inhibitor synthesis, assay development and screening for inhibitors of reversible histone acetylation and methylation.

Publikationen (Auswahl)

  • Identification of a small-molecule ligand of the epigenetic reader protein Spindlin1 via a versatile screening platform. T. Wagner, H. Greschik, T. Burgahn, K. Schmidtkunz, A.‑K. Schott, J. McMillan, L. Baranauskienė, Y. Xiong, O. Fedorov, J. Jin, U. Oppermann, D. Matulis, R. Schüle, M. Jung; Nucl. Acids Res. (2016) doi:10.1093/nar/gkw089.
  • Assembly of methylated LSD1 and CHD1 drives AR dependent transcription and translocation. E. Metzger, D. Willmann, J. McMillan, I. Forne, P. Metzger, S. Gerhardt, K. Petroll, A. von Maessenhausen, S. Urban, A.-K. Schott, A. Espejo, A. Eberlin, D.  Wohlwend, K. M. Schüle,
    M. Schleicher, S. Perner, M. T. Bedford, M. Jung, J. Dengjel, R. Flaig, A. Imhof, O. Einsle,
    R. Schüle; Nat. Struct. Mol. Biol. 23 (2016) 132-139.
  • Structure-based Development of a Sirtuin 2 Affinity Probe. M. Schiedel, T. Rumpf, B. Karaman, A. Lehotzky, S. Gerhardt, J. Ovádi, W. Sippl, O. Einsle, M. Jung; Angew. Chem. Int. Ed. 55 (2016) 2252-2256.
  • Selective Sirt2-inhibition by ligand-induced rearrangement of the active site. T. Rumpf,
    M. Schiedel, B. Karaman, C. Roessler, B. J. North, A. Lehotzky, J. Olah, K. I. Ladwein,
    K. Schmidtkunz, M. Gajer, M. Pannek, C. Steegborn, D. A. Sinclair, S. Gerhardt, J. Ovadi,
    M. Schutkowski, W. Sippl, O. Einsle, M. Jung, Nat. Commun. 6 (2015) 6263.
  • Synthesis and biological investigation of oxazole hydroxamates as highly selective histone deacetylase 6 (HDAC6) inhibitors. J. Senger, J. Melesina, M. Marek, C. Romier, I. Oehme,
    O. Witt, W. Sippl, M. Jung; J. Med. Chem. 59 (2016) 1545–1555.

FRIAS-Projekt

Chemical Epigenetics

Epigenetics is one of the major topics of modern biomedical research and is already a major focus in the Freiburg research landscape with international visibility. We will establish a Research Focus on Chemical Epigenetics that deals with epigenetic mechanisms on a molecular level using our combined expertise in synthetic organic and medicinal chemistry, structural biochemistry and bioinformatics to address this topic in a highly synergistic manner. The main scientific focus of our project will be acetyl and methyl lysine binding proteins, so called histone code readers. Structural analyses provide the basis for identification and optimization of new chemical ligands for these proteins in a rational, bioguided fashion. This will lead to new chemical tools that will allow dissecting cellular pathways involving these proteins as well as the analysis of their suitability as targets in drug discovery. The structural aim of this project is the preparation of a proposal for a structured PhD programme in Chemical Epigenetics with a strong international education perspective.